Ho, Ginny D.; Michael Seganish, W.; Bercovici, Ana; Tulshian, Deen; Greenlee, William J.; Van Rijn, Rachel; Hruza, Alan; Xiao, Li; Rindgen, Diane; Mullins, Deborra; Guzzi, Mario; Zhang, Xiaoping; Bleickardt, Carina; Hodgson, Robert published the artcile< The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia>, Quality Control of 1003-32-3, the main research area is phosphodiesterase inhibitor schizophrenia dihydroimidazoisoquinoline derivative preparation SAR.
The identification of potent and orally active dihydroimidazoisoquinolines as PDE 10A inhibitors is reported. The SAR development led to the discovery of compound 35 (I) as a potent, selective, and orally active PDE10A inhibitor. Compound 35 inhibited MK-801-induced hyperactivity at 3 mg/kg and displayed a 10-fold separation between the minimal EDs for inhibition of MK-801-induced hyperactivity and hypolocomotion in rats.
Bioorganic & Medicinal Chemistry Letters published new progress about Antipsychotics. 1003-32-3 belongs to class thiazole, and the molecular formula is C4H3NOS, Quality Control of 1003-32-3.
Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica